“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise," the company's CEO and MD Paul McKenzie said.

Australia's biotech giant CSL Ltd reported a 5% rise in its first-half profit on Tuesday, boosted by growth in its core immunoglobulin business across geographies, while low U.S. immunisation rates weighed on its influenza products unit.

CSL Limited ( ($CMXHF) ) has released its Q2 earnings. Here is a breakdown of the information CSL Limited presented to its investors. CSL Limited